Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine in Huntington's Disease (Open PRIDE-HD)
NCT02494778Phase 2Terminated
- Sponsor
- Prilenia Therapeutics
- Start
- Sep 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of pridopidine in Huntington's disease (HD), sponsored by Prilenia Therapeutics. Started Sep 2015; status: terminated.
02
Drugs
pridopidine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02494778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494778.